Drug Type Small molecule drug |
Synonyms Tripterin, celastrol |
Action antagonists, inhibitors, agonists |
Mechanism CDC37 antagonists(cell division cycle 37, HSP90 cochaperone antagonists), COMMD3 inhibitors(COMM domain containing 3 inhibitors), COMMD8 inhibitors(COMM domain containing 8 inhibitors) + [5] |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC29H38O4 |
InChIKeyKQJSQWZMSAGSHN-JJWQIEBTSA-N |
CAS Registry34157-83-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fractures, Bone | Phase 3 | Iran | 22 Dec 2023 | |
Prader-Willi Syndrome | Preclinical | United States | 10 Apr 2024 | |
Autoimmune Diseases | Preclinical | China | 31 May 2023 | |
Hepatitis C | Preclinical | China | 18 Apr 2023 | |
Diabetes Mellitus | Preclinical | United States | 04 Mar 2019 | |
Nonalcoholic Steatohepatitis | Preclinical | United States | 04 Mar 2019 | |
Obesity | Preclinical | United States | 21 May 2015 | |
Neoplasms | Preclinical | United States | 15 Apr 2011 | |
Pancreatic Cancer | Preclinical | United States | 01 Jan 2008 |
Not Applicable | FLT3 positive Acute Myeloid Leukemia FLT3 ITD mutated | - | ijvcjebodh(npkywoilkm) = celastrol treatment affected the extracellular acidification rate (ECAR) in MV-4-11 cells showing a compensatory decrease in glycolysis hladcwgykd (rgfagxjddc ) View more | - | 27 Apr 2025 | ||
Not Applicable | - | kczmuokvfk(fisfgnwzcc) = knurlspbsh vjfpwjyddq (jgltuinpzm ) View more | Positive | 01 Jun 2013 | |||
Vehicle | kczmuokvfk(fisfgnwzcc) = uggzxfejeb vjfpwjyddq (jgltuinpzm ) View more |